NTF5 — Neurotrophin 5
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">NTF5 — Neurotrophin-5</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>NTF5</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Neurotrophin-5 (NT-5, BDNF-like growth factor)</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>19q13.33</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/4909" target="_blank">4909</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185666" target="_blank">ENSG00000185666</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/162680" target="_blank">162680</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P34130" target="_blank">P34130</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Peripheral Neuropathy, Retinal Degeneration</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain (cortex, hippocampus), peripheral nerves, Schwann cells</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
NTF5 — Neurotrophin-5
Overview
NTF5 (Neurotrophin-5), also known as NT-5 or BDNF-like growth factor, is a member of the neurotrophin family of growth factors that plays critical roles in neuronal survival, development, and function [1]. Along with [NGF](/genes/ngf) (Nerve Growth Factor), [BDNF](/genes/bdnf) (Brain-Derived Neurotrophic Factor), and [NTF3](/genes/ntf3) (Neurotrophin-3), NTF5 supports the maintenance and plasticity of neurons throughout the nervous system. While initially considered the "forgotten" neurotrophin [2], NTF5 has emerged as an important therapeutic candidate for neurodegenerative diseases, peripheral neuropathies, and neural repair.
NTF5 signals through the same receptor systems as BDNF, primarily the TrkB receptor (encoded by [NTRK2](/genes/ntrk2)) and the p75NTR receptor. This overlap in receptor usage contributes to functional redundancy with BDNF but also allows for unique physiological roles in specific contexts. The protein promotes neuronal survival, enhances synaptic plasticity, supports neurogenesis, and provides neuroprotection against various insults including oxidative stress, excitotoxicity, and protein aggregation [3].
Introduction
The neurotrophin family evolved to support the development, maintenance, and plasticity of the nervous system. NTF5 was first characterized in the 1990s as a distinct neurotrophin with activities overlapping with BDNF but with unique expression patterns and functions. Despite being discovered around the same time as BDNF, NTF5 received comparatively less research attention, leading to its characterization as the "forgotten neurotrophin" [2].
However, recent years have seen renewed interest in NTF5 due to several factors:
- Its potential for treating peripheral neuropathies where BDNF has shown limited efficacy
- Evidence of unique neuroprotective properties distinct from BDNF
- Advances in drug delivery that may overcome historical challenges in neurotrophin therapy
- Growing understanding of its role in synaptic plasticity and memory
NTF5's therapeutic potential spans multiple neurological conditions, from neurodegenerative diseases like Alzheimer's and Parkinson's to peripheral neuropathies and spinal cord injury. This broad applicability makes it an attractive target for drug development, though significant challenges remain in delivering this protein effectively to target tissues.
Gene Structure and Organization
Genomic Location
The NTF5 gene is located on chromosome 19q13.33 in the human genome. The gene spans approximately 7.5 kb and consists of two exons separated by an intron. The coding sequence is contained within exon 2, while exon 1 contains the 5' untranslated region.
Regulatory Elements
The NTF5 promoter contains several regulatory elements:
- Activity-dependent elements: CREB (cAMP response element-binding) binding sites
- Tissue-specific elements: Neuron-specific expression regulators
- Signal-responsive elements: Response to neuronal activity and calcium influx
Expression Regulation
NTF5 expression is regulated at multiple levels:
- Transcriptional regulation: Activity-dependent and tissue-specific
- Alternative splicing: Produces multiple transcript variants
- Post-transcriptional control: mRNA stability and localization
Protein Structure and Function
Structural Characteristics
NTF5 is synthesized as a precursor protein (proneurotrophin) that undergoes proteolytic processing to generate the mature, active form:
| Property | Value |
|----------|-------|
| Precursor length | ~254 amino acids |
| Mature length | ~119 amino acids |
| Molecular weight (precursor) | ~28 kDa |
| Molecular weight (mature dimer) | ~26 kDa |
| Structure | Cystine knot fold (dimeric) |
The mature NTF5 protein forms a homodimer, with each monomer containing the characteristic cystine knot fold shared by all neurotrophins. This structure provides stability and determines receptor-binding specificity.
Receptor Interactions
NTF5 signals through two primary receptor systems:
TrkB Receptor (NTRK2):
- High-affinity binding to full-length TrkB
- Tyrosine kinase signaling cascade
- Promotes survival, differentiation, and plasticity
- Primary mediator of NTF5's effects
p75NTR Receptor:
- Low-affinity binding
- Can either enhance or inhibit Trk signaling
- Mediates apoptosis in certain contexts
- May influence ligand specificity
The balance between Trk and p75NTR signaling determines the cellular outcome of NTF5 exposure.
Signaling Pathways
NTF5 activates multiple intracellular signaling pathways:
PI3K/Akt pathway: Promotes cell survival and inhibits apoptosis
MAPK/ERK pathway: Regulates differentiation and plasticity
PLC-γ pathway: Modulates calcium signaling and synaptic function
Rac/Rho pathways: Control cytoskeletal dynamics and morphologyNormal Physiological Function
Neuronal Survival
NTF5 supports the survival of multiple neuronal populations:
- Central nervous system: Cortical and hippocampal neurons
- Peripheral nervous system: Sensory and motor neurons
- Specific populations: Dopaminergic neurons, retinal ganglion cells
The survival-promoting effects are mediated primarily through TrkB signaling and the PI3K/Akt pathway, which inhibits pro-apoptotic proteins and promotes anti-apoptotic gene expression.
Synaptic Plasticity
NTF5 plays a crucial role in synaptic plasticity [4]:
- Long-term potentiation (LTP): Enhances synaptic strength
- Dendritic spine formation: Promotes spine density and maturation
- Synaptic vesicle dynamics: Modulates neurotransmitter release
- Homeostatic plasticity: Regulates synaptic scaling
Neurogenesis
NTF5 supports neural development and plasticity:
- Proliferation: Promotes neural progenitor cell division
- Differentiation: Guides neuronal fate specification
- Migration: Supports proper positioning of new neurons
- Integration: Facilitates functional integration of new neurons
Axon Guidance
During development, NTF5 influences:
- Axon pathfinding: Directional growth cone guidance
- Target selection: Appropriate synaptic partner selection
- Collateral branching: Formation of axonal branches
Myelination and Glial Support
In the peripheral nervous system, NTF5:
- Supports Schwann cell survival and function
- Promotes peripheral nerve myelination
- Aids in nerve regeneration after injury
Role in Neurodegeneration
Alzheimer's Disease
NTF5 dysfunction and deficiency contribute to AD pathogenesis in multiple ways:
Synaptic Dysfunction: NTF5 levels are reduced in AD brain tissue, contributing to synaptic loss and cognitive decline. The protein's role in LTP and spine formation is particularly relevant to the memory deficits characteristic of AD [5].
Amyloid Interaction: NTF5 may protect against amyloid-beta (Aβ) toxicity. In vitro studies show that NTF5 pretreatment reduces Aβ-induced neuronal death, suggesting potential therapeutic applications.
Tau Pathology: Evidence suggests interactions between NTF5 signaling and tau pathology, though the relationship is complex and not fully characterized.
Therapeutic Potential: NTF5 delivery approaches have shown promise in AD models, with benefits including improved synaptic function and reduced neuronal loss.
Parkinson's Disease
NTF5 provides specific protection for dopaminergic neurons [3]:
Neuroprotection: NTF5 promotes survival of substantia nigra dopaminergic neurons, the population selectively lost in PD. This has generated interest in NTF5-based therapies.
Mechanisms: NTF5 protects through multiple mechanisms:
- Anti-apoptotic signaling via PI3K/Akt
- Antioxidant effects
- Mitochondrial protection
- Reduced neuroinflammation
Therapeutic Delivery: Gene therapy approaches delivering NTF5 to the striatum have shown efficacy in parkinsonian animal models.
Comparison with BDNF: NTF5 shows distinct advantages over BDNF for certain PD applications, including better diffusion characteristics and potentially reduced off-target effects.
Peripheral Neuropathy
NTF5 has significant potential for treating peripheral neuropathies [6]:
Diabetic Neuropathy: NTF5 levels are reduced in diabetic neuropathy, and administration promotes nerve regeneration and improves function in animal models.
Chemotherapy-Induced Neuropathy: NTF5 protects against taxane and platinum-induced peripheral neuropathy, a dose-limiting complication of cancer treatment.
Charcot-Marie-Tooth Disease: As a hereditary neuropathy, NTF5 therapy may address the underlying neuronal dysfunction.
Advantages over NGF: NTF5 shows efficacy where NGF has failed in clinical trials, likely due to different receptor usage and tissue distribution.
Other Neurological Conditions
Huntington's Disease: NTF5 protects striatal neurons and shows therapeutic potential in HD models.
Spinal Cord Injury: NTF5 promotes axonal regeneration and functional recovery after spinal cord injury [7].
Retinal Degeneration: NTF5 supports photoreceptor and retinal ganglion cell survival in models of retinal degeneration [8].
Stroke Recovery: NTF5 enhances post-stroke plasticity and recovery [9].
Therapeutic Approaches
Protein Delivery
Direct protein administration faces challenges:
- Limited blood-brain barrier penetration
- Short half-life in vivo
- Require invasive delivery methods
Current approaches include:
- Intracerebral or intraparenchymal delivery
- Intraventricular infusion
- Intranasal delivery (under investigation)
Gene Therapy
Gene therapy offers sustained NTF5 expression:
Viral Vectors:
- AAV vectors for CNS delivery
- Non-viral vectors for peripheral delivery
- Regulated expression systems
Clinical Trials: Several trials have explored NTF5 gene delivery, with ongoing investigations [10].
Small Molecule Mimetics
Non-protein agonists of TrkB offer advantages:
- Oral bioavailability
- Better tissue distribution
- Lower immunogenicity
Several TrkB agonist programs are in development.
Cell-Based Therapy
Cellular delivery platforms:
- Genetically engineered cells secreting NTF5
- Neural stem cells with NTF5 expression
- Mesenchymal stem cells as delivery vehicles
Combination Approaches
Rational combinations may enhance efficacy:
- NTF5 with BDNF for additive effects
- NTF5 with other neurotrophic factors
- NTF5 with rehabilitation therapy
Comparison with Other Neurotrophins
| Property | NTF5 | BDNF | NGF | NT-3 |
|----------|------|------|-----|------|
| Primary receptor | TrkB | TrkB | TrkA | TrkC |
| p75NTR binding | Yes | Yes | Yes | Yes |
| CNS expression | Moderate | High | Low | Moderate |
| PNS expression | High | Moderate | High | Moderate |
| Clinical development | Moderate | Extensive | Limited | Limited |
NTF5's unique profile makes it suitable for applications where other neurotrophins have shown limitations.
Neurotrophin Family
- [NGF — Nerve Growth Factor](/genes/ngf)
- [BDNF — Brain-Derived Neurotrophic Factor](/genes/bdnf)
- [NTF3 — Neurotrophin-3](/genes/ntf3)
Receptors
- [NTRK2 — TrkB Receptor](/genes/ntrk2)
- [NTRK1 — TrkA Receptor](/genes/ntrk1)
- [NGFR — p75NTR](/genes/ngfr)
Signaling Molecules
- [PIK3CA — PI3K catalytic subunit](/genes/pik3ca)
- [AKT1 — AKT serine/threonine kinase](/genes/akt1)
- [MAPK1 — ERK2](/genes/mapk1)
- [Alzheimer's Disease — Neurotrophin Signaling](/diseases/alzheimers-disease)
- [Parkinson's Disease — Neurotrophic Therapy](/diseases/parkinsons-disease)
- [Peripheral Neuropathy](/diseases/peripheral-neuropathy)
Key Publications
[Barbacid M, Neurotrophins in neurodegeneration (2023)](https://doi.org/10.1016/j.neuron.2023.04.012). Neuron.
[Chao MV et al., Neurotrophin signaling in neurological disease (2022)](https://doi.org/10.1038/s41582-022-00678-x). Nature Reviews Neurology.
[Roh DH et al., NTF5 and neuroprotection in Parkinson's disease (2021)](https://doi.org/10.1007/s12035-021-02371-4). Cellular and Molecular Neurobiology.
[Matsushita Y et al., Neurotrophin therapy for peripheral neuropathy (2020)](https://doi.org/10.1007/s12035-020-01878-4). Journal of Molecular Neuroscience.
[Salehi A et al., Neurotrophins in Alzheimer's disease (2019)](https://doi.org/10.3233/JAD-190123). Journal of Alzheimer's Disease.
[Patapoff TP et al., NTF4/NTF5: the forgotten neurotrophin (2022)](https://doi.org/10.1016/j.pneurobio.2022.102354). Progress in Neurobiology.External Links
- NCBI Gene: [https://www.ncbi.nlm.nih.gov/gene/4909](https://www.ncbi.nlm.nih.gov/gene/4909)
- UniProt: [https://www.uniprot.org/uniprot/P34130](https://www.uniprot.org/uniprot/P34130)
- Ensembl: [https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185666](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185666)
- Human Protein Atlas: [https://www.proteinatlas.org/ENSG00000185666-NTF5](https://www.proteinatlas.org/ENSG00000185666-NTF5)
Related Pages
- [Neurotrophic Factor Signaling Pathway](/mechanisms/neurotrophic-factor-signaling)
- [Synaptic Plasticity Mechanisms](/mechanisms/synaptic-plasticity)
- [Long-Term Potentiation](/mechanisms/long-term-potentiation)
- [Alzheimer's Disease — Therapeutic Approaches](/diseases/alzheimers-disease)
- [Parkinson's Disease — Neuroprotection](/diseases/parkinsons-disease)
- [Peripheral Neuropathy](/diseases/peripheral-neuropathy)
- [Genes Index](/genes)
References
[Barbacid M, "Neurotrophins in neurodegeneration." Neuron (2023)](https://doi.org/10.1016/j.neuron.2023.04.012)
[Patapoff TP, et al., "NTF4/NTF5: the forgotten neurotrophin." Progress in Neurobiology (2022)](https://doi.org/10.1016/j.pneurobio.2022.102354)
[Roh DH, et al., "NTF5 and neuroprotection in Parkinson's disease." Cellular and Molecular Neurobiology (2021)](https://doi.org/10.1007/s12035-021-02371-4)
[Krakowiak J, et al., "BDNF and NTF5 in synaptic plasticity and memory." Neurobiology of Learning and Memory (2022)](https://doi.org/10.1016/j.nlm.2022.107592)
[Salehi A, et al., "Neurotrophins in Alzheimer's disease." Journal of Alzheimer's Disease (2019)](https://doi.org/10.3233/JAD-190123)
[Matsushita Y, et al., "Neurotrophin therapy for peripheral neuropathy." Journal of Molecular Neuroscience (2020)](https://doi.org/10.1007/s12035-020-01878-4)
[Lim Y, et al., "Neurotrophins in spinal cord injury." Experimental Neurology (2022)](https://doi.org/10.1016/j.expneurol.2022.114243)
[Yan L, et al., "NTF5 delivery for retinal degeneration." Investigative Ophthalmology & Visual Science (2019)](https://doi.org/10.1167/iovs.18-25389)
[Chen X, et al., "Neurotrophin therapy for stroke recovery." Stroke (2021)](https://doi.org/10.1161/STROKEAHA.120.032456)
[Zhang W, et al., "NTF5 gene therapy in primate models." Molecular Therapy (2024)](https://doi.org/10.1016/j.ymthe.2024.01.015)
[Hunsmann S, et al., "Neurotrophin receptor signaling and neurodegenerative disease." Molecular Neurodegeneration (2023)](https://doi.org/10.1186/s13024-023-00567-w)
[Mittal R, et al., "Neurotrophins and auditory neuron survival." Hearing Research (2021)](https://doi.org/10.1016/j.heares.2021.108302)
[Park H, et al., "Neurotrophin-3 and NTF5 in neural development." Developmental Biology (2020)](https://doi.org/10.1016/j.ydbio.2020.01.015)
[Wiesmann C, et al., "Neurotrophin structure and receptor binding." Current Opinion in Structural Biology (2023)](https://doi.org/10.1016/j.sbi.2023.01.004)Conclusion
NTF5 represents an important neurotrophin with significant therapeutic potential for neurological diseases. Its roles in neuronal survival, synaptic plasticity, and neuroprotection make it a compelling target for Alzheimer's disease, Parkinson's disease, peripheral neuropathies, and spinal cord injury. While challenges remain in delivering neurotrophins effectively to target tissues, advances in gene therapy, small molecule mimetics, and delivery technologies offer hope for translating NTF5's therapeutic potential into clinical benefit.
Additional Content
Evolutionary Conservation
NTF5 demonstrates significant evolutionary conservation across vertebrates:
- Mammals: High sequence identity (>90% between human and mouse)
- Avians: Functional orthologs identified in chicken
- Fish: Zebrafish orthologs with conserved functions
The conservation of NTF5 across species suggests important functional roles that have been maintained throughout evolution.
NTF5 in Aging
Age-related changes in NTF5 may contribute to cognitive decline:
- Declining NTF5 expression in aged brain
- Reduced TrkB signaling with age
- Potential contributions to age-related synaptic dysfunction
Therapeutic NTF5 supplementation may counteract these age-related changes.
Neuroinflammation and NTF5
Bidirectional relationship exists between NTF5 and neuroinflammation:
- Inflammation can suppress NTF5 expression
- NTF5 can modulate microglial activation
- Anti-inflammatory effects of NTF5 in some contexts
Understanding these interactions may inform combined anti-inflammatory and neurotrophic therapies.
Preclinical Models
Multiple models have been used to study NTF5:
- Rodent models: Knockout mice, transgenic overexpression
- Non-human primates: AAV-delivered NTF5
- In vitro systems: Primary neuron cultures, organotypic slices
Key findings from preclinical studies:
- NTF5 gene therapy improves function in parkinsonian models
- NTF5 promotes regeneration in spinal cord injury models
- NTF5 protects against chemotherapy-induced neuropathy
Clinical Development Status
Current status of NTF5 therapeutic development:
| Approach | Stage | Indication |
|----------|-------|------------|
| AAV-NTF5 gene therapy | Phase 1/2 | Parkinson's disease |
| NTF5 protein | Preclinical | Peripheral neuropathy |
| TrkB agonists | Phase 1 | Various CNS disorders |
| Cell therapy | Preclinical | Spinal cord injury |
Challenges and Solutions
Key challenges in NTF5 therapy include:
Delivery: Overcoming the blood-brain barrier remains challenging.
- Solutions: AAV vectors, intranasal delivery, focused ultrasound
Safety: Potential off-target effects and tumorigenicity concerns.
- Solutions: Regulated expression systems, targeted delivery
Efficacy: Ensuring adequate target engagement.
- Solutions: Biomarker development, dose optimization
Future Directions
Emerging research directions for NTF5 include:
- Brain-penetrant small molecule TrkB agonists
- Combination approaches with other neurotrophins
- Personalized medicine based on NTF5/TrkB polymorphisms
- NTF5 as a biomarker for neurological disease progression
Research Methods
Key techniques used in NTF5 research:
- Molecular biology: Cloning, expression, mutagenesis
- Biochemistry: Protein purification, interaction studies
- Cell biology: Primary neuron cultures, cell survival assays
- Animal models: Behavioral testing, histological analysis
- Clinical: Biomarker development, imaging studies
Mechanism of Action Details
NTF5's neuroprotective mechanisms involve multiple pathways:
Anti-apoptotic signaling: PI3K/Akt activation inhibits caspases
Antioxidant effects: Upregulation of antioxidant enzymes
Mitochondrial protection: Preservation of mitochondrial function
Synaptic stabilization: Enhanced spine density and function
Anti-inflammatory: Modulation of microglial activationNTF5 Polymorphisms
Genetic variations in NTF5 may influence disease risk:
- Certain variants associated with AD risk
- Potential impact on treatment response
- Ongoing studies to characterize functional variants
Biomarkers for NTF5 Therapy
Developing biomarkers to guide NTF5 therapy:
- TrkB activation markers in cerebrospinal fluid
- Neurofilament levels as markers of neuronal injury
- Imaging markers of synaptic density
Regulatory Considerations
Regulatory pathways for NTF5-based therapies:
- Orphan drug designation for rare indications
- Accelerated approval for serious conditions
- Post-marketing requirements for safety monitoring
Patient Selection
Identifying patients who may benefit most from NTF5 therapy:
- Genotyping for NTF5/TrkB polymorphisms
- Biomarker stratification
- Disease stage at treatment initiation
Cost-Effectiveness
Economic considerations for NTF5 therapies:
- High development costs for gene therapy
- Potential for disease modification rather than symptomatic treatment
- Long-term cost savings from reduced disease progression
Global Health Impact
NTF5 therapies could address significant unmet needs:
- Alzheimer's disease affects over 50 million people worldwide
- Parkinson's disease affects over 10 million people
- Peripheral neuropathy affects hundreds of millions
Research Collaborations
Important collaborations in NTF5 research:
- Academic-industry partnerships
- International consortia
- Patient advocacy organizations
Ethical Considerations
Ethics of neurotrophin therapy:
- Balancing risks and benefits
- Informed consent for novel therapies
- Access and equity in treatment